You are here: Industry Insights > Common Stock

News List

Onconova Therapeutics Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market firstwordpharma
January 05, 2020
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock firstwordpharma
December 24, 2019
The Company has also granted the underwriters a 45-day option to purchase up to 90,959 additional shares of common stock to cover over-allotments at the public offering price.
Processa Pharmaceuticals Announces 1 For 7 Reverse Stock Split of its Common Stock firstwordpharma
December 22, 2019
The objective of the reverse stock split is to better enable the Company to qualify for a future listing on the Nasdaq Capital Market by increasing the market price per share.
XOMA Announces Closing of Rights Offering firstwordpharma
December 22, 2019
The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on December 2, 2019.
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock firstwordpharma
April 11, 2019
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) ("BDSI" or the "Company") today announced that it is ……
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock firstwordpharma
April 04, 2019
The Company intends to use the net proceeds of both offerings for research and product development activities
Matinas BioPharma Announces Proposed Public Offering of Common Stock firstwordpharma
March 15, 2019
BTIG, LLC is acting as sole book-running manager for the offering.
Bellerophon Announces Closing of $7 Million Public Offering of Common Stock firstwordpharma
January 28, 2019
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced the closing and funding of its previously announced underwritten public offering of 10,000,000 shares of its common s
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock firstwordpharma
January 15, 2019
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock.